Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.6
4.9
Journals
Marine Drugs
Special Issues
Marine Natural Products as Anticancer Agents 4.0
share announcement

Marine Natural Products as Anticancer Agents 4.0

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Pharmacology".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 541

Special Issue Editors

Dr. Celso Alves

E-Mail Website
Guest Editor
MARE—Marine and Environmental Sciences Centre, Polytechnic of Leiria, 2520-630 Peniche, Portugal
Interests: marine natural products; biotechnological applications; pharmaceutical applications; signal transduction; anticancer activities; compounds isolation
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Marc Diederich

E-Mail Website
Guest Editor
Department of Pharmacy, College of Pharmacy, Seoul National University, Building 29 Room 223, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea
Interests: oncology; signal transduction; cell death; inflammation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Based on the success of the Special Issue “Marine Natural Products as Anticancer Agents 3.0” (https://www.mdpi.com/journal/marinedrugs/special_issues/841OM8M7Q0), as well as the critical relevance of this topic, we are pleased to announce the fourth edition of this Special Issue.

This Special Issue focuses on marine organisms that produce compounds with unique chemical structures, which can be used for cancer drug discovery. The manuscripts accepted for this Special Issue will provide in-depth mechanistic insight into the molecular and cellular biology of cancer cells.

Indeed, marine compounds have mechanisms of action that are potentially different from those of drugs derived from terrestrial sources, making them highly valuable in overcoming drug resistance or targeting both solid tumors and hematological malignancies with greater precision. Recent developments in biotechnology that have created new opportunities for sustainable sourcing and production of marine-derived compounds, enabling scalable production for use in drug development, are topics of interest in the development of anticancer therapeutics. Altogether, the exploration and sustainable utilization of marine resources continue to be a promising area in the quest for new therapies to fight cancer. Hence, we look forward to the fourth edition of this Special Issue focusing on marine compounds and cancer.

Therefore, we invite academic and industry scientists to submit reviews and original and/or conceptual research articles regarding the anticancer activities of known, novel, or derived natural marine compounds, emphasizing the diversity of the molecular targets and mechanistic effects.

Dr. Celso Alves
Prof. Dr. Marc Diederich
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • anticancer
  • anti-tumor
  • immune
  • molecular targets
  • co-cultures
  • 3D culture models
  • marine natural products
  • receptors
  • proteins
  • molecular modeling
  • chemical synthesis
  • immune-modulatory

Related Special Issues

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 8540 KiB  
Article
Marizomib (Salinosporamide A) Promotes Apoptosis in A375 and G361 Melanoma Cancer Cells
by Wiktoria Monika Piskorz, Rafał Krętowski and Marzanna Cechowska-Pasko
Mar. Drugs 2024, 22(7), 315; https://doi.org/10.3390/md22070315 - 15 Jul 2024
Viewed by 403
Abstract
Malignant melanoma—a tumor originating from melanocytes—is characterized by dynamic growth and frequent metastases in the early stage of development. Current therapy methods are still insufficient, and there is a need to search for new ways of treating this malady. The induction of apoptosis—physiological [...] Read more.
Malignant melanoma—a tumor originating from melanocytes—is characterized by dynamic growth and frequent metastases in the early stage of development. Current therapy methods are still insufficient, and there is a need to search for new ways of treating this malady. The induction of apoptosis—physiological cell death—by proteasome inhibitors is recognized as an effective method of non-invasive elimination of cancer cells. In our research, we wanted to check the potential of marizomib (MZB, salinosporamide A, NPI-0052)—an irreversible proteasome inhibitor derived from the marine actinomycete Salinispora tropica—to induce apoptosis in A375 and G361 malignant melanoma cells. We determined the cytotoxic activity of marizomib by performing an MTT test. Ethidium bromide and acridine orange staining demonstrated the disruption of membrane integrity in the examined cell lines. We confirmed the proapoptotic activity of marizomib by flow cytometry with the use of an FITC-Annexin V assay. A Western blot analysis presented an increase in the expression of proteins related to endoplasmic reticulum (ER) stress as well as markers of the apoptosis. The gathered findings suggest that marizomib induced the ER stress in the examined melanoma cancer cells and directed them towards the apoptosis pathway. Full article
(This article belongs to the Special Issue Marine Natural Products as Anticancer Agents 4.0)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop